8-K Announcements
6Material company update
May 1, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Mar 10, 2026·SEC
Esperion Therapeutics, Inc.(ESPR)Earnings, Financials & Key Ratios
ESPR•NASDAQ
$3.15
Price updated Jul 6, 2026
AboutEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Show more
- Revenue$403M+21.3%
- EBITDA$60M+10.9%
- Net Income-$23M+56.2%
- EPS (Diluted)-0.11+60.7%
- Gross Margin67.95%-14.4%
- EBITDA Margin14.98%-8.6%
- Operating Margin14.95%-8.7%
- Net Margin-5.63%+63.9%
ESPR Price & Volume
Esperion Therapeutics, Inc. (ESPR) stock price & volume — 10-year historical chart
Loading chart...
Volatile Milestone Revenue Masks Structural Profitability Challenges
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Strained
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Commercial ramp-up execution risk
Key Thesis Takeaways
- Esperion Therapeutics faces a precarious financial outlook characterized by erratic revenue growth, which swung from a 52.8% contraction in 2025Q1 to a 143.7% expansion in 2025Q4, largely driven by lumpy milestone recognition rather than consistent commercial demand.
- The company's reliance on external financing is underscored by a persistent negative equity position of -$307.9M as of 2026Q1, raising significant concerns regarding long-term capital sustainability.
- Investors should monitor the firm's inability to achieve consistent operating leverage, as evidenced by the swing from an $85.2M operating profit in 2025Q4 to a $6.6M loss in 2026Q1.
Verdict Logic
the company's inability to maintain positive equity, which stood at -$307.9M in 2026Q1, combined with extreme quarterly cash flow volatility, suggests significant execution risk for long-term investors.
ESPR Growth Metrics
Esperion Therapeutics, Inc. (ESPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years12.12%
3 Years74.8%
TTM61.13%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM95.16%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM91.97%
Return on Capital
10 Years-55.74%
5 Years-37.82%
3 Years-10.6%
Last Year45.89%
ESPR Recent Earnings
Esperion Therapeutics, Inc. (ESPR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.10-150.0%
$0.04
Rev
$80M-5.2%
$85M
Q2 2026
May 7, 2026Metric
Actual
Est
EPS
$0.01+75.0%
$0.04
Rev
$84M-1.1%
$85M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.22-4.3%
$0.23
Rev
$168M+1.2%
$166M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.16-77.8%
$0.09
Rev
$87M-47.1%
$165M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.10vs $0.04-150.0% | $80Mvs $85M-5.2% |
| Q2 2026 | May 7, 2026 | $0.01vs $0.04+75.0% | $84Mvs $85M-1.1% |
| Q2 2026 | Mar 10, 2026 | $0.22vs $0.23-4.3% | $168Mvs $166M+1.2% |
| Q4 2025 | Nov 6, 2025 | $0.16vs $0.09-77.8% | $87Mvs $165M-47.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Esperion Therapeutics, Inc. (ESPR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.15 | $654.91M | -28.64 | 21.31% | -5.63% | — | — | |
| $529.48 | $12.21B | -41.20 | 432.05% | -27.32% | -50.15% | — | |
| $40.10 | $4.31B | -24.60 | — | — | -32.55% | — | |
| $9.50 | $497.36M | -2.10 | -92.84% | -260.92% | -49.88% | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — | |
| $25.77 | $4.41B | 11.25 | 11.87% | 34.3% | 35.65% | — |
Compare ESPR vs Peers
Esperion Therapeutics, Inc. (ESPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ESPR SEC Filings & Documents
Esperion Therapeutics, Inc. (ESPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ESPR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ESPR Frequently Asked Questions
Esperion Therapeutics, Inc. (ESPR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Esperion Therapeutics, Inc.'s revenue?
Esperion Therapeutics, Inc. (ESPR) reported $418.2M in revenue for fiscal year 2025.
How fast is Esperion Therapeutics, Inc. growing?
Esperion Therapeutics, Inc. (ESPR) grew revenue by 21.3% over the past year. This is strong growth.
Is ESPR profitable?
Esperion Therapeutics, Inc. (ESPR) reported a net loss of $7.4M for fiscal year 2025.
Dividend & Returns
What is Esperion Therapeutics, Inc.'s free cash flow?
Esperion Therapeutics, Inc. (ESPR) had negative free cash flow of $18.2M in fiscal year 2025, likely due to heavy capital investments.